CollabRx has appointed Paul Billings to its board of directors. Billings is a board certified internist and clinical geneticist and most recently served as chief medical officer for Life Technologies. He is executive chairman of Melanoma Diagnostics, a director of Trovagene, and a co-founder and past medical director of the Cordblood Registry. He was also a senior vice president for corporate development at Laboratory Corporation of America and a co-founder of Omicia. Billings also currently serves on the Scientific Advisory Board of the US Food and Drug Administration, the Genomic Medicine Advisory Committee at the Department of Veterans Affairs, and the National Academy of Sciences Institute of Medicines Roundtable on Genomics.

Kathy Hibbs, former senior VP and general counsel at Genomic Health, has joined 23andMe as chief legal and regulatory officer. Hibbs joins 23andMe while the firm is in the midst of regulatory discussions with the US Food and Drug Administration regarding its Personal Genome Service. Hibbs has also worked at Monogram Biosciences and Varian Medical Systems, and is actively engaged in a number of industry groups, such as the American Clinical Laboratory Association, the Coalition for 21st Century Medicine, and the Personalized Medicine Coalition.

Stephen Rusckowski has been named chairman of the American Clinical Laboratory Association's board of directors. Rusckowski has served as Quest Diagnostics' president and CEO since May 2012. Before joining Quest Diagnostics he was CEO of Philips Healthcare.

ProteinSimple has appointed Joe Keegan and Chris van Ingen to its board of directors. Keegan was previously the CEO of ForteBio and Molecular Devices. Van Ingen was previously president of Agilent Technologies' bio-analytical measurement business. He currently serves on the boards of Bruker, Accelrys, and Promega.

Read more:
Celera Researchers Investigating Genetic Risk Signature to Predict Atrial Fibrillation